Sudarshan Jain Archives - Express Pharma

US tariffs leave Indian pharma unaffected, industry voices relief

Balancing MAGA and MIGA

Dealsphere launches in India, streamlining nutraceutical licensing and commercialisation

Trumping the Budget blues?

Exemptions, concessional duty on essential medicines to improve drug access: Sudarshan Jain, IPA

Association leaders share their expectations from Budget 2025-26

Sudarshan Jain highlights Indian pharma’s path to $130 billion by 2030

Optimising spend, maximising growth

9th Advanced GMP Workshop 2024 was organised by IPA

Critical to make a clear distinction between NSQ and Spurious Drugs: IPA